Table 6.
Selected studies reporting cranial or hypoglossal neuropathies in NPC patients treated with IMRT.
| Study | No. | Median follow up (range) | Incidence CN | Incidence hypoglossal neuropathy | Notes |
|---|---|---|---|---|---|
| Lee et al. (13) | 444 | NR * | 1.6% | NR | IMRT lower rates than 2D (p=0.01) |
| Peng et al. (14) | 306** | 3.5y (0.1-6.9y) |
3.9% | NR | IMRT lower rates than 2D (p=0.02) |
| Zhang et al. (9) | 480 | 3.6y (2.9-5.4y) |
3.8% | NR | G1/2 1.7% G3/4 2.1% combined arms of study; difference between NACT and CRT |
| Li et al. (22) | 477 | 5.9y (0.1-7.5y) |
3.7% | NR | G1/2–2.3% G3/4–1.4% Combined arms of study; difference between NACT and CRT |
| McDowell et al. (40) | 107 | 7.5y (4.2-11.1) |
14% (late) | 13% | G1–6% G2–4% G3–4% |
| Chow et al. (106) | 797 | 8.1y | NR | 8.7% | 74% unilateral; 26% bilateral; |
CN, cranial neuropathy; NR, not recorded; IMRT, intensity-modualted RT; G1/2, grade 1 or 2 toxicity; G3/4, grade 3 or 4 toxicity; NACT, neoadjuvant chemotherapy; CRT, concurrent chemoradiotherapy;
*
not reported for IMRT cohort separately, for entire study range was 0.2-18.2 years including 2D, 3D and IMRT.
**
306 in IMRT arm of this study.